Bristol-Myers Squibb (BMS) has entered an agreement with the Netherlands-based molecular diagnostics developer Qiagen for the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs).
The firms plan to utilise the GEPs as predictive or prognostic tools with BMS’ new immuno-oncology (I-O) therapies for the treatment of cancer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The partnership will leverage BMS’ I-O therapies in combination with Qiagen’s NGS technologies, and its expertise in development and commercialisation of companion and complementary diagnostics.
BMS Oncology development head Fouad Namouni said: “Greater precision in the treatment of cancer may enable faster decision-making to identify which patient populations are most likely to derive benefit from our immuno-oncology agents.
“We believe working with Qiagen will help develop better diagnostic tools to target the most appropriate immunotherapies across a number of different tumour types.”
Initially, the firms intend to develop GEPs for various BMS I-O molecules, with plans for a further agreement to use the GEPs for developing new diagnostic products, as well as to extend the use of NGS technology for other BMS I-O therapies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataQiagen CEO Peer Schatz said: “Our teams at QIAGEN are looking forward to working with Bristol-Myers Squibb to leverage the power of NGS technology to potentially improve outcomes for patients.”
BMS and Qiagen have been collaborating since 2009, while their Therascreen KRAS companion/complementary diagnostic assay secured approval from the US Food and Drug Administration (FDA) in 2012.
